This update introduced key biomarkers, including1p/19q codeletion for diagnosing oligodendroglioma, and IDH mutation status, along with several other molecular markers and histologic features, to differentiate astrocytoma subtypes. This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).